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Abstract
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix
Symposium, “Genomics into Healthcare” was co-organized by the Center for Arab
Genomic Studies (CAGS - http://www.cags.org.ae) in collaboration with the Golden Helix
Foundation (http://www.goldenhelix.org) in Dubai, United Arab Emirates from 17-19
November, 2013. The meeting was attended by over 900 participants, doctors and
biomedical students from over 50 countries and was organized into a series of nine
themed sessions that covered cancer genomics and epigenetics, genomic and
epigenetic studies, genomics of blood and metabolic disorders, cytogenetic diagnosis
and molecular profiling, next generation sequencing, consanguinity and hereditary
diseases, clinical genomics, clinical applications of pharmacogenomics and genomics in
public health.
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Introduction
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix
Symposium, “Genomics into Healthcare”, hosted by Sheikh Hamdan Bin Rashid Al
Maktoum Award for Medical Sciences and organized by the Center for Arab Genomic
Studies (CAGS - http://www.cags.org.ae) in collaboration with the Golden Helix
Foundation (http://www.goldenhelix.org) was held from 17-19 November, 2013 in Dubai,
UAE. The 3-day conference was opened by His Excellency Prof. Najib Al Khaja,
Secretary General of Sheikh Hamdan Bin-Rashid Al Maktoum Award for Medical
Sciences (http://www.hmaward.org.ae) and President of CAGS.
The meeting was attended by over 900 participants, doctors and biomedical
students from over 50 countries and featured 50 lectures and over 100 poster
presentations. Sponsored by the Gulf Scientific Corporation, the meeting was organized
into a series of nine themed sessions that covered: 1) cancer genomics and epigenetics;
2) genomic and epigenetic studies; 3) genomics of blood and metabolic disorders; 4)
cytogenetic diagnosis and molecular profiling; 5) next generation sequencing; 6)
consanguinity and hereditary diseases; 7) clinical genomics; 8) clinical applications of
pharmacogenomics; and, 9) genomics in public health.

Opening Keynote
The opening Keynote lecture was given by Prof. David N. Cooper (Cardiff, UK)
on the molecular basis of reduced (or incomplete) penetrance in inherited human
disease. He discussed how reduced penetrance can be a function of factors such as
specific mutation(s), allele dosage, differential allelic expression, copy number variation
and the influence of additional genetic variants (in cis or in trans).
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Studies of Arab populations
The Arab world comprises 22 countries and extends from Mauritania in the west
to Oman in the east (Figure 1). Across this vast region also known as MENA (MiddleEast and North Africa), genetic disorders are relatively common and account for a
substantial proportion of physical and mental handicaps. Large family size, older
parental age, high consanguinity rate (40-68%), first cousin marriages and the
considerable presence of tribal groups contribute to the burden of genetic diseases in
these societies. However, despite experiencing numerous cultural, legal and religious
challenges, several Arab countries have active prevention programs for some common
genetic disorders including hemoglobinopathies and Down syndrome.
Towards the goal of collecting omics data, several large-scale genetics initiatives
relating to the Arab world were featured at the meeting. Dr. Abdul Rezzak Hamzeh
(UAE) described the work of CAGS. Founded in 2003, it hosts the “Catalogue for
Transmission

Genetics

in

Arabs”

(CTGA),

an

open-access

database

(http://cags.org.ae/ctga_search.html) that contains over 1,600 disease and gene records
and is the major global resource for genetic information in Arabs. Other initiatives include
the Genome Arabia Project that plans to sequence up to 500 individuals from seven
countries in the region including Qatar, Bahrain, Kuwait, United Arab Emirates, Tunisia,
Lebanon and Saudi Arabia using next-generation sequencing (NGS) technologies in
order

to

identify

disease-causing

mutations

(http://www.bbc.co.uk/news/health-

25216135).
The Weill-Cornell Medical College in Qatar has conducted a number of nextgeneration medical genomics projects, including family and cohort studies of diabetes,
obesity, inherited neuropathies and cancer. The data generated has been deposited in
the Qatar Genome Browser (QGB), a web-based data portal, which provides an
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interface to the public for study focused on NGS-omics data. QGB is the first of its kind
in the MENA region.
Dr. Arif Anwar from Sengenics (Malaysia; http://www.sengenics.com), the first
Asia-based genomics research and molecular diagnostics company, presented a novel
pipeline for identification of clinically significant mutations using array-comparative
genomic hybridization (a-CGH) combined with whole exome sequencing (WES). This
large-scale study of pediatric disorders in the Arab population screened approximately
1,000 samples for variants in 20,000 genes. Identification of clinically significant
mutations using combined aCGH/WES resulted in a significant increase in diagnostic
yield.
Dr. Ilham Ratbi gave an outline of the Moroccan National/Ethnic Mutation
Database

(NEMDB;

http://www.sante.gov.ma/departements/inh/mohumuda/)

was

initiated in 2007. It aims to provide researchers and clinicians with up-to-date information
about genetic variants in various genes known to cause genetic disorders that have
been detected in Moroccan patients. To date, the database contains 425 mutations and
208 polymorphisms found in 301 genes and 259 diseases. Autosomal recessive mode of
inheritance accounts for 74.17% of the genetic disease burden in the Moroccan
population. This database has recently been migrated to the new ETHNOS platform and
upgraded with new data and novel data querying and visualization tools (Papadopoulos
et al., 2014). The migration of the Moroccan NEMDB to the new ETHNOS platform is
part of a broader project involving development of new and migration of existing
NEMDBs to the upgraded ETHNOS platform that is encouraged by the Genome
Informatics

Working

Group

of

the

(www.genomicmedicinealliance.org).
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Genomic

Medicine

Alliance

Dr. Mohammed Naveed presented the results of his study in identifying the
genetic modifiers of a rare and severe limb deformity in a large Emirati family. Dr. Erol
Baysal from the Dubai Health Authority shed light on the use of chorionic villus sampling
and the latest in DNA-based diagnostics and how the accurate detection and counseling
of at-risk couples is helping to reduce the mortality and morbidity from beta-thalassemia.
Prof. Aida Al Aqeel explored the challenges as well as the progress and recent
advances in the implementation of personalized transitional genomics in the clinical
setting. She stressed that in Saudi Arabia, pre-implantation genetic diagnosis and
neonatal screening for genetic metabolic disorders are, at present, the most important
preventive programmes, and that the country is considering new therapeutic strategies,
such as personalized therapeutic strategies at the genomics level.
Additional omics-based initiatives were presented during the conference
including

the

European

Cytogeneticists

Association

Register

of

Unbalanced

Chromosome Aberrations (ECARUCA; www.ecaruca.net), which collects and provides
cytogenetic and clinical information on rare chromosomal disorders, including
microdeletions and microduplications. ECARUCA is a multi-lingual database that
contains over 2,500 types of aberrations. In the same vein, the conference included a
workshop about Rd-CONNECT (http://rd-connect.eu), which is a unique global
infrastructure project that links up databases, registries, biobanks and clinical
bioinformatics data used in research on rare diseases to act as a central resource for
researchers worldwide. Together with other two multicenter projects, namely Neuromics
(www.rd-neuromics.eu) and EURenOmics (www.rd-eurenomics.eu) coordinated by Prof.
Olaf Riess and Franz Schaefer, respectively, RD-CONNECT allows scientists to share
data from their genomics research projects leading to faster diagnosis, better treatments
and quality of life improvement for patients with rare diseases.
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Special medical issues in the Arab world
The conference highlighted some of the special medical issues in the Arab world
such as increased homozygosity due to consanguinity, which is linked to a high overall
risk of cancer. Dr. Lotfi Chouchane (Qatar) reported that breast cancer is the most
common malignant disease in women from Arab populations comprising up to 42% of all
tumors, and presenting 10 years earlier than in women from Western Europe
(Chouchane et al, 2013). It was also shown that triple negative breast cancer (i.e., any
breast cancer that does not express the genes for estrogen receptor, progesterone
receptor and Her2/neu) is more common in this part of the world. This data contrasts
with the incidence of breast cancer in Europe and the USA, where the incidence has
fallen in recent years.
Recessive disorders are highly prevalent in the UAE due to high rates of
consanguinity among many of its subpopulations. However, the molecular causes
underlying many of the rare recessive disorders are still unknown. Advances in NGS and
bioinformatics have significantly expedited the discovery of the defective genes and
mutations of many genetic conditions. Dr. Nadia Akawi (UAE) presented the UAE
experience on the usage of WES for the identification of genes and mutations of several
rare recessive disorders including those causing intellectual disability, macrocephaly,
multiple dysplasia and distinctive facial appearance. Diagnoses were also obtained in
heterogeneous cases of congenital muscular dystrophy with brain and eye anomalies,
for camptodactyly-arthropathy-coxa vara-pericarditis syndrome (Akawi et al, 2012).
A poster by Amal Al hashem and colleagues presented a study of 19,165 births
in a Saudi population that showed that consanguinity is an independent risk factor for the
high rate of birth defects in a population with a high rate of consanguineous marriages
(Saadallah and Rashed, 2007). Consanguinity has a statistically significant contribution
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in cases of genetic syndromes, and isolated renal defect. However, consanguinity has
no statistically significant contribution in cases of chromosomal aberrations, isolated
congenital heart disease and multiple malformations.
The role of inbreeding and the risk of developing type 2 diabetes (T2D) was
presented through a poster by Dr. Ibrahim Gosadi (Saudi Arabia) suggesting that
consanguinity might increase risk of T2D by earlier development of the disease, and by
strengthening possible genetic effects on fasting blood glucose.
A poster by Dr. Tim Yu and colleagues showed the contribution of consanguinity
in autism spectrum disorders (ASDs) in a study of over 200 families. Multiple
approaches, including linkage analysis, homozygosity mapping and WES, show that
consanguineous families with autistic children have a significantly different genetic
architecture than non-consanguineous families, with fewer de novo events and an
enrichment of recessive point mutations and deletions. Recessive cases also
demonstrate that ASD can be an unexpected manifestation of partial loss-of-function
mutations in genes with more classical syndromic associations, and illustrate how further
study of consanguineous ASD families will be important in dissecting this complex and
heterogeneous disorder.
Prof. Hanan Hamamy provided a highly instructive talk on the feasibility of
applying new technologies to help consanguineous couples at risk of having affected
children. These techniques could help in the detection of shared known autosomal
recessive pathogenic variants giving the opportunity for these couples to decide on their
reproductive options.
Furthermore, a significant number of the presentations and posters addressed
specific problems in Arab countries including: birth defects and genetic conditions in
Oman (Prof. Anna Rajab); breast cancer and hearing loss in Palestine (Dr. Moien Nihad
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Kanaan); pharmacogenetics of warfarin metabolism, oral-facial-digital type 1 syndrome
and geleophysic dysplasia in UAE (Dr. Hayat Aljebeji); intellectual and developmental
disabilities in Lebanon (Prof. Andre Megarbane); autosomal recessive disorders,
myeloproliferative neoplasms, and copy number variants in Qatar (Dr. Tawfeg BenOmran and Dr. Khalid Fakhro); nasopharyngeal carcinoma, psoriasis and breast cancer
risk in Tunisians (Dr. Wijden Mahfoudh); mutated ANKRD26 gene and familial
thrombocytopenia. in Saudi Arabia (Dr. Walid Dridi); hypertriglyceridemia and risk of
coronary artery disease (CAD) in arterial hypertensive Moroccan patients (Dr. Sanaa
Ouatou); genetic polymorphisms and cardiovascular risk factors of Alzheimer disease in
Algerian population (Dr. Ouldjaoui Ahmed); and novel mutations in the NLRP7 gene in
two Egyptian families (Dr. Ebtesam Abdalla).

Pharmacogenomics
Pharmacogenomics holds promise to rationalize drug use by increasing drug
efficacy and minimizing drug toxicity. In developing countries, pharmacogenomics can
also contribute towards reducing healthcare expenditure at a national level. Prof. George
Patrinos (Greece) presented preliminary data indicating that there are significant
differences

among

various

European

populations

regarding

pharmacogenomic

biomarkers allele frequencies that can be readily applicable to rationalize drug use in
these countries (Mette et al., 2012). Also, he presented data from whole genome
sequence analysis of 482 unrelated individuals of various ethnic backgrounds to obtain
their personalized pharmacogenomic profiles, indicating that a significant number of
novel pharmacogenomically relevant variants can be identified using this approach
(Mizzi et al, submitted). Also, these findings were replicated in a 7-member family of
Greek origin in an effort to explain the variable response rate to acenocoumarol
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treatment in two family members. Overall, these data demonstrate that whole genome
sequencing is necessary to accurately determine an individual’s pharmacogenomics
profile.
Additional clinical applications of pharmacogenomics were illustrated by Prof.
Ron van Schaik, who described the work at his laboratory. They have offered PGx
testing in close collaboration with the hospital pharmacy since 2005 and have tested
over 2,000 patients. The fifteen different markers, most commonly ordered involve the
TPMT and CYP2D6 genes, including the HLA-A*3101 with a growth rate of 40-50% tests
requests per year (Elens et al, 2013). In this context, an important PGx resource is
Pharmacogenomics Knowledge Base (PharmGKB, www.pharmgkb.org), a publicly
available Internet research tool developed by Stanford University that encompasses
clinical information including dosing guidelines and drug labels, potentially clinically
actionable gene-drug associations, and genotype-phenotype relationships. PharmGKB
collects curates and disseminates knowledge about the impact of human genetic
variation on drug responses.

Large-scale sequencing projects
Another theme running through the conference was how to implement largescale sequencing projects on very large groups. The largest of these initiatives is “The
Million Human Genomes Project” launched in November 2011 by Beijing Genomics
Institute (BGI; http://www.genomics.cn) to decode the genome of over 1 million people.
Features of this project, illustrated by Prof. Jun Wang (BGI, Beijing, China), comprise
five essential parts: 1) Ancient genomes; 2) Population genomes; 3) Medical genomes;
4) Cell genomes; and, 5) Personal genomes. The aim of this project is to establish a
research baseline and reference standard for specific populations, as well as to connect
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the phenotypes of diseases and traits with the genetic variations in order to understand
the disease mechanism. The integrative genome message and scientific discoveries
obtaining from the project will lay the foundation for guiding innovative clinical diagnosis
and treatment, and ultimately advancing personalized healthcare and improving human
health

(http://www.genomics.cn/en/navigation/show_navigation?nid=5658).

The

technology employed for this endeavor was shown by Dr. Radoje Drmanac, who
illustrated the benefit and advantages of nanoarrays for sequencing at several terabases per day per instrument (Drmanac et al, 2010).

Genomics into Healthcare
The conference highlighted a number of issues at the interface of genomics and
healthcare and the importance of NGS. Prof. Hilger Ropers (Germany) discussed
intellectual disability (ID) and presented a novel diagnostic tool that utilizes WES and a
proprietary algorithm to detect mutations in most of the presently known ID genes. This
work is based on a previously described test for ~600 severe recessive childhood
disorders (Bell et al, 2010) and on a comprehensive list of genes implicated in ID.
Furthermore, he anticipated that the technology will shed light on the molecular causes
of ID and related conditions such as autism, schizophrenia and epilepsy, which are still
largely unknown.
Prof. Maurizio Ferrari (Italy) showed his work with 91 patients that resulted in the
identification of novel variants which could be critical for improving risk stratification and
clinical management of

asymptomatic

patients

with Brugada syndrome. The

predisposition for these patients to develop fatal arrhythmias cannot be easily predicted
and no anti-arrhythmic drug is effective in preventing these life-threatening arrhythmias.
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Prof. Ahmad Al Marzouqi’s lecture introduced three new chromatin remodelers
that have been identified by his team: Fun30, Irc5 and Irc20. All three complexes share
some common features, including the presence of a distinct ATPase domain.
How the transcriptional and epigenetic programs interact on the chromatin
encompassing the human alpha globin cluster and its regulatory elements on
chromosome 16 was shown by Prof. Douglas Higgs. The interaction was uncovered,
using a variety of approaches to show how genes within their natural chromosomal
environment are switched on and off during hematopoiesis. These findings add to our
general understanding of the relationship between genome structure and function.
The aldehyde dehydrogenase (ALDH) superfamily (19 genes in the human
genome) is of increasing interest. Prof. Vasilis Vasilou (USA) presented work on the
recent discovery of ALDHs as markers of cancer stem cells and their involvement in
cancer cell resistance to chemotherapy and radiotherapy. As a result, it is anticipated
that ALDH may be a therapeutic target in cancer in the near future.
Prof. Achilleas Gravanis (Greece) described his work on the neuroprotective
actions of microneurotrophins in various animal models of neurodegenerative diseases
as well as in fetal and adult neural stem cells. Microneurotrophins may serve as lead
molecules to develop neurotrophin-like small molecules that can cross the blood-brain
barrier with potential applications in the treatment of neurodegenerative diseases.

Closing Keynote
The meeting closed with a keynote speech by Prof. Angela Brand (The
Netherlands) on “Genomics in Public Health”. She stressed the need to change our
perspective from diseases to diseasomes, risk factor to risk pattern, clinical utility to
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personal utility, and from complex disorders to multiple rare diseases (Brand, 2012). This
is in line with P4 Medicine (predictive, personalized, preemptive and participatory) and
the anticipated era of precision medicine (Hood and Flores, 2012). Dr. Brand described
public health genomics (PHG), the area of public health ensuring that scientific advances
in genomics are effectively and responsibly translated into health policies and practices
for the benefit of population health, and the connected activities needed for its
implementation (Brand, 2012). Her Institute aims to fulfill this task for European Member
States via the European Centre for Public Health Genomics (ECPHG).

Conclusions
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix
Symposium offered a highly valuable opportunity for Arab scientists to join forces with
international geneticists in order to accelerate the advancement of human genetics
worldwide.

The

importance

of

this

event

stemmed

from

bringing

together

multidisciplinary expertise with the goal of improving medical care. In fact the worldwide
divide between “blue sky” research and clinical practice is a huge barrier to applying
recent advances in genomics into the practice of medicine. This divide was directly
targeted by this conference, which met its objectives of attracting top-level research and
making scientists and medical professionals think of their work in a new way so as to
serve the ultimate goal: a healthier society through cutting-edge scientific discoveries.
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Figure Legends
Figure 1.
Map of the Arab World (Algeria,
Algeria, Bahrain, Comoros, Djibouti, Egypt, Iraq, Jordan, Kuwait,
Lebanon, Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia,
Sudan, Syria, Tunisia, United Arab Emirates, Yemen (Western Sahara is a disputed
territory).

Comoros

is

not

(http://en.wikipedia.org/wiki/File:Arab_World_Green.png#filelinks
http://en.wikipedia.org/wiki/File:Arab_World_Green.png#filelinks)
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